Nightingale Research Logo
Obstructive Sleep Apnoea (moderate to severe) and Overweight – Using CPAP

Obstructive Sleep Apnoea (moderate to severe) and Overweight – Using CPAP

NOW RECRUITING
-
Adelaide SA

Efficacy and Safety of a new medication in Participants with Obstructive Sleep Apnea and Obesity or Overweight who are not diabetic.

  • Age > 18 years
  • BMI ≥27kg/m2
  • Not diabetic
  • Known moderate to severe OSA (free repeat sleep study during screening)
  • At least one self reported unsuccessful dietary effort to reduce body weight
  • No planned or prior surgery for obesity (some exceptions)
  • No active cancer or history of cancer in last 5 years (some exceptions)
  • Not taking Ozempic/Mounjaro within 90 days of screening
  • weekly self- injection
Outpatient Visit
  • Screening Visit
  • Clinic visit every 4 weeks
Payment / Remuneration
  • Clinic visits $75
  • Fasting visit meal reimbursement $48
Information for Practitioners
  • Renal impairment eGFR <30mL/min/1.73m2
  • Evidence of autoimmune disease with treatment of systemic glucorticoids
  • History of MI, CVA, Angina, revascularisation, heart failure hospitalisation within 90 days of screening
  • No history of unstable mental health disorder within last 2 years
Send to*South Australia|Victoria